ERBB2 and invasive breast carcinoma: For women with HoR-positive, HER2-negative, node-negative or up to 3 lymph nodes-positive invasive breast cancer at high clinical risk, the ECIBC GDG suggests using the 70-GS test to guide the use of chemotherapy.